ArticleOPEN ACCESS

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

American Journal of Hematology
DOI: 10.1002/ajh.24981
3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Godet, S., Protin, C., Dupuis, J., Dartigeas, C., Bastie, J. N., Herbaux, C., … Quinquenel, A. (2018, February 1). Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). American Journal of Hematology. Wiley-Liss Inc. https://doi.org/10.1002/ajh.24981

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free